Distinguished in Hyperthyroidism

Zhongyan Y. Shan

72 Xiangya Road, 
Changsha, CN 
Distinguished in Hyperthyroidism
72 Xiangya Road, 
Changsha, CN 
OverviewLocationsClinical Research

Overview

Zhongyan Shan practices in Changsha, China. Shan is rated as a Distinguished expert by MediFind in the treatment of Hyperthyroidism. Their top areas of expertise are Hypothyroidism, Hyperthyroidism, Hashimoto Thyroiditis, Hormone Replacement Therapy (HRT), and Thyroidectomy.

Their clinical research consists of co-authoring 326 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 40 articles in the study of Hyperthyroidism.

Locations

72 Xiangya Road, Changsha, 410008, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including Rearranged in Transfection (RET) Fusion-Positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
A Phase 2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including Rearranged in Transfection (RET) Fusion-Positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 2
Phase III Study of Chiglitazar in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control Despite Diet and Exercise -- A Multicenter, Randomized, Double-Blind, and Sitagliptin-Controlled Trial
Phase III Study of Chiglitazar in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control Despite Diet and Exercise -- A Multicenter, Randomized, Double-Blind, and Sitagliptin-Controlled Trial
Enrollment Status: Completed
Publish Date: October 25, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

326 Total Publications

IGF-1R Inhibitor IBI311 for the Treatment of Active Thyroid Eye Disease in Chinese Patients: The RESTORE-1 Randomized Clinical Trial.
IGF-1R Inhibitor IBI311 for the Treatment of Active Thyroid Eye Disease in Chinese Patients: The RESTORE-1 Randomized Clinical Trial.
Journal: JAMA ophthalmology
Published: October 09, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Shan's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 7 Advanced Conditions
    View All 30 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile